Table 2.

Pharmacological efficacy of cannabinoid products tested in clinical trials.

Clinical Trial Number/Year	Patients	Description	Results	References
NCT02224560/2018	Adults and children (2–55 years of age, n = 225) with Lennox-Gastaut syndrome	Randomized, double-blind trial 14-week study of two dose levels (10 mg/kg/day and 20 mg/kg/day), to evaluate the efficacy and safety of CBD (GWP42003-P)	It confirmed a reduction in the number of seizures	[59]
NCT02224690/2015	Patients (2-55 years of age) with Lennox-Gastaut syndrome (n = 171)	GWP42003-P in a single dose of 20 mg/kg/day for 14 weeks	The results confirmed the reduction in seizure frequency after administration	[60]
NCT02091206/	Children (4–10 years) suffering from Dravet syndrome (n = 34)	It was a safety and pharmacokinetic dose-ranging study of Epidiolex (5, 10 and 20 mg/kg/day) with a duration of 21 days	Results confirmed that Epidiolex is a safe drug; however, it caused more adverse effects than placebo did	[61]
NCT02091375/ 2015	Children and adults (2–18 years) with Dravet syndrome (n = 120)	Evaluation of the antiepileptic efficacy of GWP42003-P	Results confirmed that CBD (20 mg/kg/day/14 weeks) resulted in 43% of the patients experiencing a reduction in seizure frequency of 50% or more. Three of these patients became seizure-free	[62]
NCT02700412/ 2015	Eighty epileptic subjects between 18 and 99 years	This interventional study evaluated the safety and tolerability of Epidiolex at various doses between 5 and 50 mg/kg/day as an add-on drug for the treatment of drug-resistant debilitating epilepsy	Results confirmed Epidiolex seizure reduction in 63.6% of patients after 12 weeks of treatment	[63]
NCT02695537/ 2015	Children and adults (1–19 years), n = 89	Evaluation of the safety and tolerability of Epidiolex for the treatment of drug-resistant debilitating epilepsy	The results confirmed after administration of various doses between 5 and 50 mg/kg/day a seizure reduction of 63.6% after 12 weeks of treatment	[63]